66 results
424B3
NBSE
NeuBase Therapeutics Inc
10 Aug 23
Prospectus supplement
5:13pm
RNA targets, if desired) and interacting with cellular machinery that processes mutant genes to halt their ability to manifest a disease.
We have
S-1
NBSE
NeuBase Therapeutics Inc
28 Jul 23
IPO registration
6:03am
. These compounds operate by temporarily engaging the genome (or single and double-stranded RNA targets, if desired) and interacting with cellular
424B5
NBSE
NeuBase Therapeutics Inc
30 Jun 23
Prospectus supplement for primary offering
8:42am
-stranded RNA targets, if desired) and interacting with cellular machinery that processes mutant genes to halt their ability to manifest a disease.
We … -stranded DNA molecules) which bind to defective RNA targets in cells and inhibit their ability to form defective proteins. We believe we are a leader
10-QT
zs25f5jb vck
5 Jun 23
Quarterly report for transitional period
4:05pm
8-K
EX-99.1
x7x7od5y
22 May 23
Regulation FD Disclosure
7:00am
8-K
EX-99.2
cj3i48
22 May 23
Regulation FD Disclosure
7:00am
424B5
hf4po0 h3
29 Dec 22
Prospectus supplement for primary offering
5:03pm
8-K
EX-99.1
0si0d65xfl3u1
11 Aug 22
NeuBase Therapeutics Reports Business Update and Financial Results for the Third Quarter of Fiscal Year 2022
8:05am
8-K
EX-99.1
8w1h0z25ah2u
14 Mar 22
Regulation FD Disclosure
6:07am
8-K
EX-99.2
zg0yi7b8w0y6vg2p84a
14 Mar 22
Regulation FD Disclosure
6:07am
8-K
EX-99.1
9nbml
23 Dec 21
NeuBase Therapeutics Reports Business Update and Financial Results for Fiscal Year 2021
4:02pm
424B5
ivrjrjtg6 sq2zlr
27 Aug 21
Prospectus supplement for primary offering
5:21pm